SG11202005873QA - Fusion protein comprising il-2 protein and cd80 protein, and use thereof - Google Patents
Fusion protein comprising il-2 protein and cd80 protein, and use thereofInfo
- Publication number
- SG11202005873QA SG11202005873QA SG11202005873QA SG11202005873QA SG11202005873QA SG 11202005873Q A SG11202005873Q A SG 11202005873QA SG 11202005873Q A SG11202005873Q A SG 11202005873QA SG 11202005873Q A SG11202005873Q A SG 11202005873QA SG 11202005873Q A SG11202005873Q A SG 11202005873QA
- Authority
- SG
- Singapore
- Prior art keywords
- protein
- fusion
- fusion protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180110698 | 2018-09-17 | ||
| KR20190001867 | 2019-01-07 | ||
| US201962832013P | 2019-04-10 | 2019-04-10 | |
| KR20190053436 | 2019-05-08 | ||
| PCT/KR2019/011928 WO2020060122A1 (en) | 2018-09-17 | 2019-09-16 | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005873QA true SG11202005873QA (en) | 2020-07-29 |
Family
ID=69887592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005873QA SG11202005873QA (en) | 2018-09-17 | 2019-09-16 | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11492384B2 (en) |
| EP (1) | EP3715367A4 (en) |
| JP (2) | JP7085644B2 (en) |
| KR (2) | KR102201086B1 (en) |
| CN (1) | CN111971295A (en) |
| AU (1) | AU2019343850A1 (en) |
| BR (1) | BR112020015030A2 (en) |
| CA (1) | CA3086486A1 (en) |
| CL (1) | CL2020001872A1 (en) |
| IL (1) | IL275592B (en) |
| MX (1) | MX2020007072A (en) |
| PE (1) | PE20201418A1 (en) |
| PH (1) | PH12020551026A1 (en) |
| SG (1) | SG11202005873QA (en) |
| TW (2) | TWI824258B (en) |
| WO (1) | WO2020060122A1 (en) |
| ZA (1) | ZA202003645B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7461741B2 (en) * | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | Anti-PD-L1 and IL-2 Cytokines |
| JP7381750B2 (en) * | 2019-11-20 | 2023-11-15 | ジーアイ・セル・インコーポレイテッド | Composition for culturing natural killer cells and method for producing natural killer cells using the same |
| MX2022006295A (en) * | 2019-11-27 | 2022-06-08 | Gi Cell Inc | Composition for anticancer treatment, comprising nk cells and fusion protein which comprises il-2 protein and cd80 protein. |
| CN115989238A (en) * | 2020-03-18 | 2023-04-18 | Gi医诺微新 | Fusion proteins comprising IL-2 protein and CD80 protein fragments or variants thereof and uses thereof |
| WO2021187897A1 (en) | 2020-03-18 | 2021-09-23 | (주)지아이이노베이션 | Fusion protein preparation comprising il-2 and cd80 proteins |
| CN115297881A (en) | 2020-03-18 | 2022-11-04 | Gi 医诺微新 | Pharmaceutical composition for treating cancer comprising fusion protein comprising IL-2 protein and CD80 protein and anticancer drug |
| AR121713A1 (en) * | 2020-03-31 | 2022-06-29 | Hanmi Pharm Ind Co Ltd | NEW IL-2 IMMUNOSTIMULANTS ANALOGS |
| WO2021238904A1 (en) * | 2020-05-25 | 2021-12-02 | 北京比洋生物技术有限公司 | Fc-cd80 fusion protein and conjugate thereof, and use thereof |
| KR102373965B1 (en) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Pharmaceutical composition for enhancing radiotherapy containing fusion protein comprising il-2 protein and cd80 protein |
| EP4174088A4 (en) * | 2020-06-30 | 2024-01-24 | Gi Innovation Inc | Fusion protein comprising anti-lag-3 antibody and il-2, and use thereof |
| US20230322881A1 (en) * | 2020-08-31 | 2023-10-12 | Gi Cell, Inc. | Fusion protein including il15 protein, il15 receptor alpha protein, fc domain, and il2 protein, and use thereof |
| TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
| WO2022057696A2 (en) * | 2021-09-08 | 2022-03-24 | 中南大学湘雅医院 | Recombinant protein coding sequence, recombinant protein, and method for preparing monoclonal antibodies |
| KR20230168273A (en) * | 2022-06-03 | 2023-12-13 | (주)지아이이노베이션 | Bispecific antibody comprising anti-tigit antibody and use thereof |
| KR20240000394A (en) * | 2022-06-22 | 2024-01-02 | (주)지아이이노베이션 | Fusion protein comprising anti-cd73 antibody and il-2 and use thereof |
| WO2024063546A1 (en) * | 2022-09-20 | 2024-03-28 | 주식회사 지아이바이옴 | Combined therapy of lactobacillus plantarum strain, and cancer treatment method using same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0119621A1 (en) * | 1983-03-21 | 1984-09-26 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Interleukin-2 |
| CN86104525A (en) * | 1985-07-31 | 1987-02-25 | 武田药品工业株式会社 | The analytical approach of human interleukin-2 and reagent |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| DZ2788A1 (en) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Selective IL-2 agonists and antagonists. |
| GB9810999D0 (en) | 1998-05-21 | 1998-07-22 | Goken Joop | Materials and methods relating to the expression of genes |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| JP2005507870A (en) * | 2001-08-13 | 2005-03-24 | ユニバーシティ・オブ・サザン・カリフォルニア | Low toxicity interleukin-2 mutant |
| PT1454138E (en) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
| RU2006135112A (en) * | 2004-03-05 | 2008-04-10 | Чирон Корпорейшн (Us) | IN VITRO TEST SYSTEM FOR FORECASTING PATIENT RESISTANCE TO THERAPEUTIC MEDICINES |
| DK1996220T4 (en) * | 2006-03-06 | 2023-11-13 | Amunix Operating Inc | UNSTRUCTURED RECOMBINANT POLYMERS AND THEIR USES |
| EP2038417A2 (en) * | 2006-07-06 | 2009-03-25 | Merck Patent GmbH | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| CA2695374A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| CU23923B1 (en) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY |
| DK3489255T3 (en) | 2011-02-10 | 2021-08-23 | Roche Glycart Ag | Mutated interleukin-2 polypeptides |
| EA201892619A1 (en) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
| US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| EP2970436B1 (en) * | 2013-03-15 | 2018-09-05 | AbbVie Biotherapeutics Inc. | Fc variants |
| SI3186283T1 (en) | 2014-08-29 | 2020-04-30 | F. Hoffmann-La Roche Ag | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
| EP3371208A1 (en) * | 2015-11-02 | 2018-09-12 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
| JP7461741B2 (en) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | Anti-PD-L1 and IL-2 Cytokines |
| US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102461885B1 (en) * | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
-
2019
- 2019-09-16 MX MX2020007072A patent/MX2020007072A/en unknown
- 2019-09-16 BR BR112020015030-4A patent/BR112020015030A2/en unknown
- 2019-09-16 WO PCT/KR2019/011928 patent/WO2020060122A1/en unknown
- 2019-09-16 US US16/959,312 patent/US11492384B2/en active Active
- 2019-09-16 JP JP2020562067A patent/JP7085644B2/en active Active
- 2019-09-16 AU AU2019343850A patent/AU2019343850A1/en active Pending
- 2019-09-16 CN CN201980025699.8A patent/CN111971295A/en active Pending
- 2019-09-16 PE PE2020000980A patent/PE20201418A1/en unknown
- 2019-09-16 KR KR1020190113659A patent/KR102201086B1/en active IP Right Grant
- 2019-09-16 SG SG11202005873QA patent/SG11202005873QA/en unknown
- 2019-09-16 EP EP19862449.6A patent/EP3715367A4/en active Pending
- 2019-09-16 CA CA3086486A patent/CA3086486A1/en active Pending
- 2019-09-17 TW TW110122590A patent/TWI824258B/en active
- 2019-09-17 TW TW108133398A patent/TWI755630B/en active
-
2020
- 2020-06-17 ZA ZA2020/03645A patent/ZA202003645B/en unknown
- 2020-06-22 IL IL275592A patent/IL275592B/en unknown
- 2020-06-30 PH PH12020551026A patent/PH12020551026A1/en unknown
- 2020-07-14 CL CL2020001872A patent/CL2020001872A1/en unknown
-
2021
- 2021-01-05 KR KR1020210000775A patent/KR102558191B1/en active IP Right Grant
-
2022
- 2022-04-21 JP JP2022070213A patent/JP2022115876A/en active Pending
- 2022-08-01 US US17/878,664 patent/US20220380781A1/en active Pending
- 2022-08-01 US US17/878,703 patent/US20220389070A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210008110A (en) | 2021-01-20 |
| CL2020001872A1 (en) | 2020-12-18 |
| PE20201418A1 (en) | 2020-12-09 |
| MX2020007072A (en) | 2020-11-11 |
| KR102201086B1 (en) | 2021-01-11 |
| KR102201086B9 (en) | 2022-10-21 |
| KR102558191B1 (en) | 2023-07-24 |
| EP3715367A4 (en) | 2021-05-05 |
| WO2020060122A1 (en) | 2020-03-26 |
| JP2022115876A (en) | 2022-08-09 |
| US20220389070A1 (en) | 2022-12-08 |
| JP2021511081A (en) | 2021-05-06 |
| US20200369740A1 (en) | 2020-11-26 |
| US20220380781A1 (en) | 2022-12-01 |
| CA3086486A1 (en) | 2020-03-26 |
| ZA202003645B (en) | 2022-09-28 |
| TWI824258B (en) | 2023-12-01 |
| IL275592A (en) | 2020-08-31 |
| KR20200032009A (en) | 2020-03-25 |
| CN111971295A (en) | 2020-11-20 |
| JP7085644B2 (en) | 2022-06-16 |
| TWI755630B (en) | 2022-02-21 |
| BR112020015030A2 (en) | 2021-03-16 |
| EP3715367A1 (en) | 2020-09-30 |
| TW202136288A (en) | 2021-10-01 |
| AU2019343850A1 (en) | 2020-06-25 |
| IL275592B (en) | 2022-02-01 |
| US11492384B2 (en) | 2022-11-08 |
| PH12020551026A1 (en) | 2021-09-06 |
| TW202028227A (en) | 2020-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275592B (en) | Fusion protein comprising il-2 protein and cd80 protein, and use thereof | |
| EP3623389A4 (en) | Fusion protein containing tgf- receptor and medicinal uses thereof | |
| EP3817822A4 (en) | Protein degraders and uses thereof | |
| EP3806889A4 (en) | Cytokine fusion proteins and uses thereof | |
| EP3737666A4 (en) | Protein degraders and uses thereof | |
| EP3684365A4 (en) | Protein degraders and uses thereof | |
| SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
| EP3147298A4 (en) | Pd-l1 fusion protein and use thereof | |
| EP3633034A4 (en) | MODIFIED Cas9 PROTEIN AND USE THEREOF | |
| EP3680331A4 (en) | Modified cas9 protein, and use thereof | |
| EP3722305A4 (en) | Hm-3 fusion protein and use thereof | |
| EP3626747A4 (en) | Novel recombinant bifunctional fusion protein, preparation method therefor and use thereof | |
| EP3810172A4 (en) | Heterodimeric proteins and uses thereof | |
| ZA202103259B (en) | Modified cas9 protein, and use thereof | |
| EP3882277A4 (en) | Fusion protein and use thereof | |
| EP3604343A4 (en) | Fusion protein, preparation method therefor and use thereof | |
| EP3668551A4 (en) | Apom-fc fusion proteins and uses thereof | |
| ZA202000595B (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| SG11202110400QA (en) | Fusion protein and use thereof | |
| IL287601A (en) | Cd80 variant proteins and uses thereof | |
| EP3876631A4 (en) | Distributed unit, central unit, and methods therefor | |
| IL279057A (en) | Endolysin-containing antimicrobial fusion proteins and uses thereof | |
| EP3856895A4 (en) | Bihaptenized autologous vaccines and uses thereof | |
| EP3831945A4 (en) | Protein heterodimer and use thereof | |
| EP3816186A4 (en) | Pd-l1-binding polypeptide and use thereof |